| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615662 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 34 Pages |
Abstract
As per base-case analyses, an adequate discount on ibrutinib is required to make it cost-effective as per the UK thresholds. The scenario analysis substantiates ibrutinib's cost-savings for the UK National Health Services and advocates patient's access to ibrutinib in the UK.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Richa Sinha, William Ken Redekop,